Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach

被引:28
|
作者
Abdi, Z. Daher [1 ,3 ]
Essig, M. [1 ,2 ,3 ]
Rizopoulos, D. [4 ]
Le Meur, Y. [5 ]
Premaud, A. [1 ,3 ]
Woillard, J. B. [1 ,3 ]
Rerolle, J. P. [1 ,2 ]
Marquet, P. [1 ,3 ,6 ]
Rousseau, A. [1 ,3 ]
机构
[1] INSERM, UMR S850, F-87025 Limoges, France
[2] CHU Limoges, Serv Nephrol Dialyse & Transplantat, F-87042 Limoges, France
[3] Univ Limoges, Lab Pharmacol Med, F-87025 Limoges, France
[4] Erasmus MC, Dept Biostat, Rotterdam, Netherlands
[5] CHU Brest, Serv Nephrol, F-29285 Brest, France
[6] CHU Limoges, Serv Pharmacol Toxicol & Pharmacovigilance, F-87042 Limoges, France
关键词
Mycophenolic acid; Renal-transplant recipients; Longitudinal exposure; Acute rejection; Joint modeling; ROC thresholds; EARLY STEROID WITHDRAWAL; TO-EVENT DATA; KIDNEY-TRANSPLANTATION; PHARMACOKINETIC PARAMETERS; RISK-FACTORS; MOFETIL; TIME; TACROLIMUS; OUTCOMES; CYCLOSPORINE;
D O I
10.1016/j.phrs.2013.03.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study aimed to investigate the association between longitudinal exposure to mycophenolic acid (MPA) and acute rejection (AR) risk in the first year after renal transplantation, and to propose MPA exposure targets conditionally to this association. A joint model, adjusted for monitoring strategy (fixed-dose versus concentration-controlled) and recipient age, was developed; it combined a mixed-effects model to describe the whole pattern of MPA exposure (i.e. area under the concentration-time curve (AUC)) and a survival model. MPA AUC thresholds were determined using time-dependent receiver-operating characteristics (ROC) curves. Data from 490 adult renal-transplant recipients, representative of the general population of adult renal-transplant patients (i.e. including patients considered at low immunological risk-enrolled in the OPERA trial as well as second renal transplant and patients co-treated by either cyclosporine or tacrolimus), were analyzed. A significant association was found between the longitudinal exposure to MPA (MPA AUCs = f(t)) and AR (p = 0.0081), and validated by bootstrapping. A significant positive correlation was observed between time post-transplantation and ROC thresholds which increased in average from 35 mg h/L in the first days to 41 mg h/L beyond six months post-transplantation (p < 0.001). Using a new modeling approach which recognizes the repeated measures in a same patient, this study supports the association between MPA exposure and AR. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:52 / 60
页数:9
相关论文
共 38 条
  • [31] Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study
    Boric-Bilusic, A. Ana
    Bozina, Nada
    Lalic, Zdenka
    Lovric, Mila
    Nad-Skegro, Sandra
    Penezic, Luka
    Barisic, Karmela
    Trkulja, Vladimir
    ADVANCES IN THERAPY, 2023, 40 (02) : 601 - 618
  • [32] Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients
    Cai, W.
    Cai, Q.
    Xiong, N.
    Qin, Y.
    Lai, L.
    Sun, X.
    Hu, Y.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (05) : 1298 - 1304
  • [33] A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
    Robertsen, Ida
    Debord, Jean
    Asberg, Anders
    Marquet, Pierre
    Woillard, Jean-Baptiste
    CLINICAL PHARMACOKINETICS, 2018, 57 (11) : 1459 - 1469
  • [34] Clinical impact using low-dose mycophenolate mofetil with tacrolimus on infectious, noninfectious complications and acute rejection, in renal transplant: A single hospital experience in Mexico
    Andrade-Sierra, Jorge
    Hernandez-Reyes, Hernesto
    Rojas-Campos, Enrique
    Cardona-Munoz, Ernesto German
    Cerrillos-Gutierrez, Jose Ignacio
    Gonzalez-Espinoza, Eduardo
    Evangelista-Carrillo, Luis Alberto
    Medina-Perez, Miguel
    Jalomo-Martinez, Basilio
    Miranda-Diaz, Alejandra Guillermina
    Martinez-Mejia, Victor Manuel
    Gomez-Navarro, Benjamin
    Andrade-Ortega, Antonio de Jesus
    Nieves-Hernandez, Juan Jose
    Mendoza-Cerpa, Claudia Alejandra
    MEDICINE, 2023, 102 (46) : E35841
  • [35] Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol
    Pelletier, R. P.
    Soule, J.
    Henry, M. L.
    Rajab, A.
    Ferguson, R. M.
    CLINICAL TRANSPLANTATION, 2007, 21 (04) : 532 - 535
  • [36] Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study
    A Ana Borić-Bilušić
    Nada Božina
    Zdenka Lalić
    Mila Lovrić
    Sandra Nađ-Škegro
    Luka Penezić
    Karmela Barišić
    Vladimir Trkulja
    Advances in Therapy, 2023, 40 : 601 - 618
  • [37] Therapeutic drug monitoring of mycophenolic acid (MPA) using volumetric absorptive microsampling (VAMS) in pediatric renal transplant recipients: ultra-high-performance liquid chromatography-tandem mass spectrometry analytical method development, cross-validation, and clinical application
    Kocur, Arkadiusz
    Rubik, Jacek
    Czarnowski, Pawel
    Czajkowska, Agnieszka
    Marszalek, Dorota
    Sierakowski, Maciej
    Gorska, Marta
    Pawinski, Tomasz
    PHARMACOLOGICAL REPORTS, 2023, 75 (04) : 1026 - 1042
  • [38] Therapeutic drug monitoring of mycophenolic acid (MPA) using volumetric absorptive microsampling (VAMS) in pediatric renal transplant recipients: ultra-high-performance liquid chromatography-tandem mass spectrometry analytical method development, cross-validation, and clinical application
    Arkadiusz Kocur
    Jacek Rubik
    Paweł Czarnowski
    Agnieszka Czajkowska
    Dorota Marszałek
    Maciej Sierakowski
    Marta Górska
    Tomasz Pawiński
    Pharmacological Reports, 2023, 75 : 1026 - 1042